ODIN Therapeutics

Odin Therapeutics is a Norwegian biotechnology company focused on developing novel small molecule inhibitors of tankyrase (TNKS) for the treatment of fibrotic diseases and cancer. A spin-off from the University of Oslo and Oslo University Hospital, the company leverages deep expertise in the Wnt/beta-catenin and YAP signaling pathways to address hyperproliferative and profibrotic disorders. Its lead candidate, OM-153, has demonstrated robust preclinical efficacy in models of idiopathic pulmonary fibrosis (IPF) by counteracting profibrotic changes and reducing extracellular matrix protein synthesis. The company is currently advancing its portfolio toward Investigational New Drug (IND) enabling studies, with a primary focus on respiratory and oncological indications.